Biomarker Lens

Common biomarkers

  • Hemoglobin
  • Glucose
  • ALT
  • Apolipoprotein B
  • C-Reactive Protein, Cardiac
  • Ferritin
  • Alb/Creat Ratio, Urine
  • Alkaline Phosphatase
  • FSH
  • T4,Free(Direct)

Biomarkers · Chemical

AFP Value

An AFP test is a blood test that measures the level of alpha-fetoprotein (AFP) in your blood when you are pregnant. The test checks your baby's risk of having certain birth defects and genetic problems, but it does not diagnose any health conditions.

Alpha-Fetoprotein (AFP) Test, MedlinePlus, National Library of Medicine

Primary unit
ng/mL
LOINC codes
1834-1
Tests that measure AFP Value
Quest Diagnostics 9, Labcorp 7

Ranges

Each lab publishes a reference range for the population groups it tests, usually the middle 95% of results. These intervals describe that population, not an optimal or healthy target. How ranges differ

Quest Diagnostics, Alpha-Fetoprotein (AFP) and AFP-L3 19529

PopulationInterval
AFP1.6-4.5 ng/mL
AFP-L30.5-9.9 %

Quest Diagnostics test catalog, 19529

Tests

Check the catalog code, specimen, method and preparation for every test that measures AFP Value. Select up to five tests to compare them side by side.

Quest Diagnostics 9 tests

Panels that include this biomarker

  • Alpha-Fetoprotein (AFP) and AFP-L3 19529

    2 analytes · Serum · Fasting not stated · Turnaround Set up: Tues; Report available: 2 days

    Method and collection
    Method
    Liquid-Phase Binding Assay System
    Quest Diagnostics catalog page

  • Maternal Serum AFP 5059

    2 analytes · Serum · Fasting not stated · Turnaround Set up: Mon-Fri (Day shift); Report available: 4 days

    Method and collection
    Method
    Immunoassay (IA)
    Collection
    For manual orders use “Maternal Serum Screen Requisition " The maternal serum AFP test in pregnant women should be performed between 15.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial MSAFP results are abnormal. Specimens submitted before 15.0 weeks or after 22.9 weeks gestation cannot be properly evaluated. The Maternal Serum Screen Requisition designed to obtain patient data and the patient's informed consent must be utilized when ordering the maternal serum AFP test. Because the maternal serum AFP test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: Date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient diabetic status (is patient insulin dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
    Quest Diagnostics catalog page

  • Hepatocellular Carcinoma Panel 16222

    3 analytes · Serum · Fasting not stated

    Method and collection
    Method
    Liquid-Phase Binding Assay System • Immunoassay (IA)
    Reference notes
    AFP 1.6-4.5 ng/mL AFP-L3 0.5-9.9 % DCP <7.5 ng/mL
    Quest Diagnostics catalog page

  • Quad Screen 30294

    4 analytes · Serum · Fasting not stated · Turnaround Set up: Mon-Fri (Day shift); Report available: 4 days

    Method and collection
    Method
    Immunoassay (IA)
    Collection
    For manual orders use "Maternal Serum Screen Requisition" The Quad test in pregnant women should be performed between 14.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial Quad Screen test results are abnormal. Specimens submitted before 14.0 weeks or after 22.9 weeks gestation cannot be properly evaluated for open neural tube defects, Down Syndrome or Trisomy 18. The Maternal Serum Screen Requisition designed to obtain patient data and the patient's informed consent must be utilized when ordering the Quad Screen test. Because the Quad Screen test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient's diabetic status (is patient insulin dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
    Reference notes
    See Laboratory Report
    Quest Diagnostics catalog page

  • Sequential Integrated Screen, Part 2 16133

    4 analytes · Serum · Fasting not stated

    Method and collection
    Method
    Chemiluminescence (CL) • Immunoassay (IA)
    Collection
    Collect between 14.0 to 22 6/7 weeks. Maternal date of birth (mm/dd/yy), Estimated Date of Delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results. Must complete patient demographic information using the Maternal Serum Screen Requisition.
    Reference notes
    See Laboratory Report
    Quest Diagnostics catalog page

Labcorp 7 tests

Panels that include this biomarker

  • α-Fetoprotein (AFP) With AFP-L3% 141300

    2 analytes · Serum · Fasting not stated · Turnaround 1 - 3 days

    Method and collection
    Method
    Liquid-phase binding assay
    Collection
    If a red-top tube is used, transfer separated serum to a plastic transport tube.
    Reference notes
    See table. Age Male Female AFP, Serum (ng/mL) AFP, Serum (ng/mL) 0 to 7 d 0.0–75265.8 0.0–75265.8 8 to 30 d 0.0–32556.4 0.0–32556.4 1 m 0.0–1747.8 0.0–1600.3 2 m 0.0–391.1 0.0–550.0 3 m 0.0–225.8 0.0–339.9 4 m 0.0–230.6 0.0–230.6 5 m 0.0–118.0 0.0–234.0 6 m 0.0–97.2 0.0–97.2 7 to 11 m 0.0–60.3 0.0–60.3 1 y 0.0–21.4 0.0–21.4 2 y 0.0–9.4 0.0–10.1 3 to 4 y 0.0–5.5 0.0–5.5 5 y 0.0–3.6 0.0–4.2 6 to 12 y 0.0–3.9 0.0–3.9 13 to 17 y 0.0–4.3 0.0–4.3 18 to 30 y 0.0–5.7 0.0–4.7 31 to 50 y 0.0–6.9 0.0–6.4 51 to 80 y 0.0–8.4 0.0–9.2 >80 y 0.0–6.4 0.0–8.7 Reference Interval developed by in-house study. Normal values apply only to males and to nonpregnant females. These results are not interpretable for pregnant females. AFP-L3%, Serum All 0.0–9.9 0.0–9.9
    Labcorp catalog page

  • α-Fetoprotein (AFP) With AFP-L3% (Serial Monitor) 480300

    2 analytes · Specimen not stated · Fasting not stated · Turnaround 6 - 7 days

    Labcorp catalog page

  • α-Fetoprotein (AFP), Maternal Serum for Open Spina Bifida 010801

    4 analytes · Serum · Fasting not stated · Turnaround 2 - 5 days

    Method and collection
    Method
    Chemiluminescent immunoassay
    Collection
    Collect in serum separator tube with gel barrier. Allow blood to clot, avoiding hemolysis. Separate serum from cells by centrifugation. Transport spun tube to testing laboratory. Pour-off is not advised. Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
    Labcorp catalog page

  • α-Fetoprotein (AFP) Tetra Profile 017319

    13 analytes · Serum · Fasting not stated · Turnaround 2 - 5 days

    Method and collection
    Method
    Chemiluminescent immunoassay
    Collection
    Collect in serum separator tube with gel barrier. Allow blood to clot, avoiding hemolysis. Separate serum from cells by centrifugation. Transport spun tube to testing laboratory. Pour-off is not advised. Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
    Labcorp catalog page

  • Serum Integrated 2 017270

    16 analytes · Serum · Fasting not stated · Turnaround 2 - 5 days

    Method and collection
    Method
    Chemiluminescent immunoassay
    Collection
    Collect in serum separator tube with gel barrier. Allow blood to clot, avoiding hemolysis. Separate serum from cells by centrifugation. Transport spun tube to testing laboratory. Pour-off is not advised. Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
    Labcorp catalog page

0 of 5 tests selected

Pick one more

Sources

Verify these ranges and sources

We compile this page from named laboratory catalogs, guidelines and studies. Labs calculate reference intervals from the people they test, for one assay method and one population group, so an interval describes that population rather than an optimal target.

Interpret your own results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.